CM
BCRX icon

Caption Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Caption Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$390K – 1567
2025
Q4 		$390K Buy
+50,000
New +$361K ﹤0.01% 1284
2025
Q3 		– Sell
-20,000
Closed -$179K – 1666
2025
Q2 		$179K Buy
+20,000
New +$186K ﹤0.01% 1273
2025
Q1 		– Sell
-296,500
Closed -$2.23M – 1525
2024
Q4 		$2.23M Buy
+296,500
New +$2.25M 0.02% 655
2024
Q3 		– Sell
-72,100
Closed -$446K – 1279
2024
Q2 		$446K Buy
72,100
+22,100
+44% +$122K 0.01% 829
2024
Q1 		$254K Hold
50,000
– – ﹤0.01% 974
2023
Q4 		$300K Buy
+50,000
New +$290K ﹤0.01% 1060
2023
Q2 		– Sell
-40,000
Closed -$334K – 1106
2023
Q1 		$334K Sell
40,000
-115,800
-74% -$1.11M 0.01% 864
2022
Q4 		$1.79M Buy
155,800
+84,700
+119% +$1.06M 0.03% 585
2022
Q3 		$895K Sell
71,100
-534,600
-88% -$6.88M 0.01% 901
2022
Q2 		$6.41M Buy
605,700
+118,200
+24% +$1.22M 0.09% 280
2022
Q1 		$7.92M Buy
487,500
+217,500
+81% +$3.49M 0.1% 290
2021
Q4 		$3.74M Sell
270,000
-125,000
-32% -$1.65M 0.04% 554
2021
Q3 		$5.68M Sell
395,000
-490,000
-55% -$7.73M 0.06% 401
2021
Q2 		$14M Buy
885,000
+790,000
+832% +$10.7M 0.18% 133
2021
Q1 		$966K Buy
+95,000
New +$980K 0.02% 696
2019
Q3 		– Sell
-20,000
Closed -$76K – 708
2019
Q2 		$76K Buy
+20,000
New +$120K ﹤0.01% 616

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caption Management's BCRX Position: Q1 2025 in Review

Caption Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 62,789 shares — an estimated $472K sold.

Caption Management first reported a position in BCRX in Q1 2019 and held it in 13 quarters. The position peaked at $7.98M in Q2 2021. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

  • Caption Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 62,789 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $472K.
  • Caption Management first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 13 quarters.
  • Caption Management's BioCryst Pharmaceuticals position peaked at $7.98M in Q2 2021.
  • 274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.